SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for its motion sickness drug, NEREUS, marking the first new treatment in this category in decades. The community is actively discussing the significant upside potential, fueled by this approval and upcoming PDUFA dates for other pipeline candidates, with many highlighting its potential off-label use for GLP-1 induced nausea. Traders are debating whether to hold for long-term growth driven by a diversified portfolio or capitalize on immediate short-term volatility.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp ($BULL) is trending amid intense community debate, largely driven by ongoing price depreciation attributed to tax loss harvesting and persistent selling pressure from SPAC-related share overhang. Despite recent inclusion in the Russell 2000/3000 indexes and reported strong revenue growth in its latest quarter, sentiment remains highly polarized. Bulls view the stock as deeply undervalued with significant long-term potential from user growth and international expansion, while bears warn of continued dilution and question the company's valuation.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending due to significant community discussion surrounding an ongoing, repeatedly postponed proxy vote on share authorization, creating considerable market uncertainty. Investors are sharply divided, with many expressing frustration over potential dilution and management's communication, while others advocate for the shares as crucial for strategic acquisitions like Ask Sage and future growth. Despite current price stagnation, a core of optimism persists for the company's potential to secure substantial government contracts and leverage its AI capabilities within the defense and national security sectors.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is a top trending meme coin, fueled by an exceptionally active community passionately advocating its status as an "OG meme" originating from Rage Comics. This dedicated base is consistently building out an ecosystem with projects like RageMaker and RageGames, expressing strong conviction for substantial long-term growth and widespread recognition in the crypto space. They are frequently seen battling other meme coins for trending dominance and market attention.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid sharp investor division, primarily driven by the recent FDA approval of Novo Nordisk's oral Wegovy pill and speculation around potential distribution partnerships for GLP-1 treatments. While many note the stock's significant drawdown and high short interest as bearish indicators, others view the current valuation as a prime long-term buying opportunity, citing strong fundamentals, institutional accumulation, and the company's expansion into new health verticals and international markets. The community is actively debating whether the current dip sets the stage for a short squeeze or further decline for the direct-to-consumer telehealth provider.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending amidst growing investor frustration as the stock continues to mark new lows, fueling intense debate around its management team and the prolonged absence of a permanent CEO. The community is actively discussing the disconnect between the acclaimed vehicle technology and the company's market performance, with many questioning impending production targets and speculating on potential short squeezes or further strategic shifts.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is currently seeing divided community sentiment, with many anticipating a potential rebound in the new year following year-end tax loss selling. Enthusiasts are holding strong, highlighting its robust community and long-term potential, while critics dismiss it as a "shit coin" with no utility. This dynamic conversation reflects the ongoing speculation about its future trajectory within the volatile crypto market.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics Holdings is capturing market attention following a proposed business combination with Applied Digital, which would see Applied Digital's cloud GPU business spun off into ChronoScale, an AI compute platform. The potential "AI merger" is fueling fervent discussion among traders, with many anticipating a significant run due to the stock's low float, while others express concerns about potential shareholder dilution.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is at the center of investor attention with a highly anticipated regulatory decision for its Cushing's syndrome drug, relacorilant, prompting intense community debate and significant trading volume. Traders are closely watching for an approval or a potential Complete Response Letter, weighing recent sector approvals against CORT's price action and broader pipeline, including its ovarian cancer program, which fuels long-term bullish sentiment despite short-term uncertainty.

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals is gaining significant attention following its substantial special cash dividend and a strategic shift towards evaluating blockchain-based assets, sparking both bullish excitement and investor debate. The community is actively discussing the stock's impressive rally, with many weighing short squeeze potential against concerns of a pump-and-dump scenario fueled by future dilution or offerings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>H.C. Wainwright conservatively expects approval by the middle of 2026 and sees the shares trading well into the year-end.</li><li>Capricor’s bumper rally on Wednesday helped the stock turn green for the year.</li><li>Retail sees the stock as a long-term winner following the Phase 3 results.</li></ul>Two decades after its modest beginnings and more than a decade after becoming a public company, San Diego, California-based Capricor Therapeutics made another stride toward becoming a commercial-stage company. After a failed first try, the small-cap biotech is hoping to push its experimental cell-therapy for a rare genetic muscular disorder past the finish line without any hiccups.Wall Street analysts and the investment community received the recently released late-stage trial data for the treatment candidate well. While sell-side analysts were generous with their price target hikes, signaling their excitement toward the data, investors sent the stock up by over 530% at one point in Wednesday’s session. The initial euphoria faded slightly, but didn’t die out, as<a href="https://stocktwits.com/symbol/CAPR">&nbsp;Capricor’s stock</a> had enough verve to finish the day up 371% at $29.96,&nbsp;ending at an eight-year high and marking its best day ever.<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_04_at_2_28_48_AM_png_599beb080a.webp" alt="Screenshot 2025-12-04 at 2.28.48 AM.png">Source: Koyfin<h2 class="st-heading-2">What Fueled CAPR’s Stratospheric Rally</h2>Wednesday, before the market opened, Capricor reported positive topline results from the Phase 3 study, dubbed HOPE-3, evaluating its Duchenne Muscular Dystrophy (DMD) cell therapy candidate, Deramiocel.-The primary endpoint, measured as the performance of upper limb (PUL), was met — showing statistically and clinically meaningful treatment effects in 54% of the patients.-The key secondary endpoint of “Left Ventricular Ejection Fraction (LVEF),” a measure of heart health, was also met.&nbsp;Thus, Deramiocel was shown to produce significant skeletal and cardiac benefits, supporting its credentials as a potential “first-in-class therapy” for Duchenne cardiomyopathy, the leading cause of mortality in DMD. The trial also gave the cell therapy a clean chit for its safety and tolerability.Capricor said it would submit the detailed results from the HOPE-3 study at a future scientific meeting and for publication in a peer-reviewed journal.Earlier in July, the FDA shot down Capricor’s initial application for Deramiocel, issuing a complete response letter (CRL) — a notice that an application cannot be approved in its current form. The agency expressed wariness about the company's efficacy data at the time and sought additional data. Industry experts saw it as a signal that the new leadership at the FDA could be veering toward a cautious approach.&nbsp;&nbsp;CEO Linda Marbán said the study results, in addition to the evidence from the HOPE-2 and HOPE-2 OLE studies, would address the clinical issues in the CRL and support regulatory approval.DMD is caused by a mutation in the DMD gene that prevents the body from producing the protein dystrophin. A lack of dystrophin hits muscle fibres, leading to muscle damage and loss.&nbsp;<h2 class="st-heading-2">What’s At Stake For Capricor</h2>According to Grand View Research, the DMD drugs<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.grandviewresearch.com/industry-analysis/duchenne-muscular-dystrophy-dmd-drugs-market">&nbsp;market</a> is expected to grow at a compounded annual growth rate (CAGR) of 16.8% from 2024, reaching $9.91 billion in 2030. North America’s revenue share was at 45% in 2023. Global Data, meanwhile, has a more muted forecast, predicting a $5.2 billion market opportunity in 2033.&nbsp;<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_04_at_3_25_08_AM_png_f4173223fa.webp" alt="Screenshot 2025-12-04 at 3.25.08 AM.png">Source: Grandview ResearchThe DMD market is currently led by Sarepta, which has a gene-replacement therapy called Eteplirsen. Elevidys, a one-time single-dose gene transfer therapy, was approved in June 2023, and its label was expanded a year later to include patients ages four and older. The gene therapy generated $131.5 million in revenue for Sarepta in the third quarter.Capricor’s Deramiocel differs from Elevidys in that it is a cell therapy that administers the patient's cardiosphere-derived cells, which secrete exosomes. The latter uses a manufactured gene for delivering the micro-dysrophin gene.Sarepta also has three FDA-approved exon-skipping therapies, Exondys 51, Amondys 45 and Vyondys 53, and it is also currently working on RNA therapies.<h2 class="st-heading-2">Big Price Target Bumps</h2>Following the data, H.C. Wainwright upped the price target for Capricor's stock to $60 from $24 and kept a 'Buy' rating, the Fly reported. The firm called the data a "decisive" win. With 78% of participants having underlying cardiomyopathy, the trial results addressed FDA concerns about sample size, the firm said. It conservatively expects approval by the middle of 2026 and sees the shares trading well into the year-end.Alliance Global called the data "unequivocally and wholly positive" and removed the speculative tag from the stock. The firm hiked its price target for the stock to $48 from $16.<h2 class="st-heading-2">Retail Convinced Of Capricor Opportunity</h2>On Stocktwits, retail investors held an 'extremely bullish' stance on Capricor stock as of early Thursday. The message volume on the stream was 'extremely high as well.A majority of retail traders are sold on Capricor's long-term potential. An ongoing Stocktwits poll asking users "What's your move on $CAPR after this Phase 3 win?" found that 53% of respondents said "This is legit — CAPR becomes a long-term winner," while 18% remained on the sidelines, waiting for approval to come through. About 29% shrugged off the rally as an "overreaction."<a href="https://stocktwits.com/StocktwitsPolls/message/638043423"><img src="https://news.stocktwits-cdn.com/CAPR_Stocktwits_poll_png_bc7624531b.webp" alt="CAPR Stocktwits poll.png"></a>CAPR stock has&nbsp;soared about 117% this year, as Wednesday's bumper rally helped it recoup all its losses to that point and turn green for the year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/core-weave-vs-nebius-ai-infra-s-breakout-duo-backed-by-nvidia-is-outrunning-big-tech/cLIXYiKRE12">&nbsp;</a><a href="https://stocktwits.com/news-articles/markets/equity/whispers-of-an-apple-deal-rebooted-intel-s-year/cLIXAvERE1L">Whispers Of An Apple Deal Rebooted Intel’s Year — Now The Market’s Asking Whether The Old Chip Giant Can Rise Again</a>

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Capricor’s Red-Hot Rally Has Wall Street And Retail Hooked — And Fresh DMD Data Could Keep Fueling The Fire

 DMD patients may soon gain access to a therapy that not only targets muscle decline but also tackles heart complications — the leading cause of death in this rare genetic disorder.

Equity

 DMD patients may soon gain access to a therapy that not only targets muscle decline but also tackles heart complications — the leading cause of death in this rare genetic disorder.


Biotech ETFs Hovering Around a 52-Week: Here's Why 

Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?

Biotech ETFs Bounce Back in 2025: Here's Why  

Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.

Shares of Compass Pathways Plc. (CMPS) slumped 47% on Monday afternoon after the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx">results</a> from the late-stage trials of COMP360 in treatment-resistant depression fell short of market expectations.COMP360 is a synthetic, proprietary formulation of psilocybin. Psilocybin is part of a group of drugs called psychedelics or hallucinogens with the ability to alter one’s sense of perception.Compass Pathways said that a single dose of the drug reduced symptom severity by 3.6 points from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) as compared to placebo at week 6.The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.The company is also running another late-stage trial for the drug, which aims to evaluate the efficacy of two fixed doses taken three weeks apart.According to Compass Pathways, an estimated 21 million adults in the U.S. suffer from major depression, and approximately 9 million are drug-treated.Approximately a third of patients with major depressive disorder will develop treatment-resistant depression, which is defined as an inadequate response to two or more appropriate courses of approved medications.Following the announcement, Evercore ISI downgraded Compass Pathways to ‘In Line’ from ‘Outperform’ with a price target of $6, down from $11.The reduction in symptom severity by 3.6 points as compared to placebo on a standardized depression scale "underwhelmed," the analyst told investors, as per TheFly.This dataset does indicate Compass may have an approvable drug, but the firm noted that durability is a key component for commercial success, and this will remain a question with relatively unclear durability in a mid-stage trial and a weaker effect at 6 weeks in the late-stage trial.H.C. Wainright, however, is more optimistic and noted that the results from the late-stage study mark "a historic first for a psychedelic therapy." The data also positions COMP360 as "a potential first-in-class treatment in a large, underserved depression market," said the analyst, who reiterated a ‘Buy’ rating and $45 price target on the shares.On Stocktwits, retail sentiment around CMPS jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:631/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_23_at_12_27_47_PM_png_d7e1356560.webp" alt="CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits" width="631" height="60"><figcaption>CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that while the late-stage results were good, the market wants ‘groundbreaking’ results.<stembedurl>https://stocktwits.com/aaronmag13/message/618680560</stembedurl><a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> is down by about 35% this year and nearly 61% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/rezolve-ai-to-be-added-to-russell-indices-after-revenue-surge/chm57C7RRdR">Rezolve Ai To Be Added To Russell Indices After Revenue Surge: Retail Echoes Confidence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts

The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.

Nasdaq-listed shares of Autolus Therapeutics PLC (AUTL) were in the spotlight on Friday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-announces-positive-chmp-opinion">announced</a> that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) approve its Obe-cel therapy for the treatment of a particular type of blood cancer.Obe-cel is short for Obecabtagene Autoleucel. The CHMP has recommended that the European Commission approve it for the treatment of adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia, an aggressive type of blood cancer that can also involve the lymph nodes, spleen, liver, central nervous system, and other organs.According to Autolus, there are about 6,000 new cases of acute Lymphoblastic Leukemia diagnosed every year in Europe.The committee’s recommendation was based on the results of the company’s open-label, multiple-centre study and will serve as the basis for the commission’s final decision on Autolus’ marketing authorization application.The European Commission's decision will apply to all 27 European Union Member States, Iceland, Norway, and Liechtenstein.Obe-cel received approval from the U.S. Food and Drug Administration in November 2024 and conditional marketing authorization from the U.K.’s Medicines and Healthcare Products Regulatory Agency in April.On Stocktwits, retail sentiment around AUTL improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume remained at ‘neutral’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_23_at_12_01_00_PM_png_a607fcc3b0.webp" alt="AUTL's Sentiment Meter and Message Volume as of 12:00 p.m. ET on May 23, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>AUTL's Sentiment Meter and Message Volume as of 12:00 p.m. ET on May 23, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism about the therapy receiving approval in the EU.<stembedurl>https://stocktwits.com/Mancunian/message/615691105</stembedurl><a href="https://stocktwits.com/symbol/AUTL">AUTL stock</a> is down by about 42% this year and 61% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/amazon-backed-anthropic-claude-blackmails-engineer/ch0QVgWRbqH">Amazon-Backed Anthropic's AI Model Reportedly Blackmails Engineer Having An Affair To Avoid Being Shut Down In Test Run</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens

CHMP has recommended that the European Commission approve the therapy for treating adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia. 

Shares of biotech Galapagos NV (GLPG) dipped nearly 1% in pre-market trade on Tuesday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.glpg.com/press-releases/galapagos-announces-departure-of-thad-huston-cfo-and-coo-as-of-august-1-2025/">announced</a> the departure of its CFO and COO, Thad Huston, effective August 1, 2025.The company said Huston has decided to leave and return to the U.S. for personal and professional reasons. It added that it expects to announce a new CFO “in the coming months,” but did not share a definitive timeline.Huston joined Galapagos in July 2023 from Kite Pharma, Inc. Before that, he worked for over 25 years at Johnson &amp; Johnson.CEO Paul Stoffels said that Huston will stay in his role until Aug. 1 to “ensure a smooth handover of responsibilities.”Galapagos, which has operations in Europe and the U.S., reported its full-year 2024 financial results earlier this year. The company logged a 15% jump in total net revenue to €275.6 million (about $312 million), while diluted earnings per share fell to $1.12 from $3.21 year-over-year (YoY).As of the end of 2024, it had €3.3 billion in cash and financial investments and said that it intends to separate into two publicly traded companies and establish SpinCo with approximately €2.45 billion in current cash.A shareholder meeting regarding the separation of Galapagos into two publicly traded entities is expected to be convened in mid-2025.On Stocktwits, retail sentiment about Galapagos fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:650/148;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_15_at_8_24_57_AM_png_80bd7d6071.webp" alt="GLPG's Sentiment Meter and Message Volume as of 8:25 a.m. ET on April 14, 2025 | Source: Stocktwits" width="650" height="148"><figcaption>GLPG's Sentiment Meter and Message Volume as of 8:25 a.m. ET on April 14, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/GLPG">GLPG stock</a> is down by over 13% year-to-date and by nearly 19% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/johnson-and-johnsons-q1-earnings-beat-estimates/chQRaxWRbaH">Johnson &amp; Johnson’s Q1 Earnings Beat Estimates, 2025 Guidance Revised To Account For Intra-Cellular Therapies Acquisition: Retail’s Positive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com(Exchange Rate: 1 Euro = 1.13 USD)

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Galapagos Announces CFO Exit With No Successor Named Yet: Retail’s Disappointed

The company expects to announce a new CFO “in the coming months.”

MoonLake Immunotherapeutics, a clinical-stage biotech firm valued at $2.6 billion, is generating excitement with its experimental treatment for hidradenitis suppurativa (HS), a chronic and painful skin condition.&nbsp;On Friday, Goldman Sachs upgraded the stock to a&nbsp;'Buy' from&nbsp;'Neutral,' with analyst Richard Law raising the price target from $62 to $82 — an 85% upside from current levels, CNBC&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/01/17/this-little-known-biotech-stock-is-a-buy-thats-primed-to-double-in-price-goldman-says.html">reported</a>.While MoonLake is gaining traction among institutional investors, it remains underfollowed on Stocktwits, with fewer than 600 watchers.&nbsp;Over the past year, retail interest has been budding, with a 12% increase in followers, even as the stock has fallen 26%.Law reportedly believes MoonLake's experimental nanobody treatment, sonelokimab (SLK), holds transformative potential.&nbsp;SLK demonstrated impressive efficacy in phase 2 trials, leading to optimism about its success in phase 3.&nbsp;Additionally, SLK's inclusion of AbbVie's Skyrizi — currently the standard of care for psoriatic arthritis (PsA) — as a reference treatment offers a key differentiator, according to the analyst.Law suggests that while this adds some risk, the potential to position SLK as superior in a competitive market far outweighs the drawbacks.Goldman Sachs isn't alone in its optimism. Oppenheimer included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.&nbsp;The brokerage sees biotech equities as undervalued relative to other sectors, with strong catalysts like lower interest rates, robust M&amp;A prospects, and transformative data releases creating a favorable backdrop this year.MoonLake ended the third quarter (Q3) of 2024 with $493.9 million in cash, cash equivalents, and marketable securities, which the company said provides a runway through 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Over the past year, retail interest has been budding, with a 12% increase in followers, even as the stock has fallen 26%.

Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely?

Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.

SBIO
ALPS Fund Services - ALPS Medical Breakthroughs ETF

Feed

News

Sentiment

Fundamentals

Info

Latest SBIO News

SBIOALPS Fund Services - ALPS Medical Breakthroughs ETF